Abstract: PO0333
CKD Decreases Cardiac PGC-1α Through Activin A Disrupting Mitochondrial Function
Session Information
- Bone and Mineral Metabolism: Basic
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Bone and Mineral Metabolism
- 401 Bone and Mineral Metabolism: Basic
Authors
- Williams, Matthew James, Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States
- Devalaraja-Narashimha, Kishor B., Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States
- Hruska, Keith A., Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States
Background
The CKD-MBD syndrome is a cause of cardiac risk. Our hypothesis was that a new component of the syndrome, activin A, is responsible for systemic activation of activin receptor (ActRII) signaling in kidney disease, and is a mechanism of cardiac disease.
Methods
Two models of CKD were employed, Col4A5 Alport Syndrome mice and ablative CKD in Rosa26 cre ERT+/inhbafl/fl mice.
Inhibition of Activin A in CKD was accomplished by either knockdown in Rosa26 cre ERT+/inhbafl/fl CKD mice or by monoclonal antibody in Alport mice.
PGC-1α, mitochondrial gene expression and oxidative phosphorylation were measured by PCR and western analysis
Cardiac mitochondrial respiration was measured by respirometry.
Results
In two kidney disease models, we show that activin A is the responsible ligand for cardiac and aortic ActRIIA activation in CKD. In untreated CKD mice, cardiac levels of pSmad2 and inhibin βa mRNA and preprotein (activin A monomer) were increased. Activin A inhibition, accomplished by either knockdown in Rosa26 cre ERT+/inhbafl/fl CKD mice or by monoclonal antibody in Alport mice, prevents CKD-induced cardiac ActRIIA activation and loss of PGC-1α, the master regulator of mitochondrial biogenesis and fatty acid oxidative phosphorylation. Mitochondrial gene expression and oxidative phosphorylation were decreased by CKD but prevented by activin A inhibition in CKD. Cardiac hypertrophy by echocardiography and heart weight was increased by CKD and prevented by activin A inhibition in the absence of vascular stiffness and without change in FGF23 levels. .
Conclusion
We conclude that activation of cardiac activin/ActRIIA signaling by CKD induces mitochondrial dysfunction through decreased PGC-1α which contributes to compensated cardiac hypertrophy in the early stages of CKD associated cardiac disease.
Funding
- NIDDK Support –